We are live on ! Find out more
TAK icon

Takeda Pharmaceutical

307 hedge funds and large institutions have $1.19B invested in Takeda Pharmaceutical in 2023 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 63 increasing their positions, 125 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,398% more call options, than puts

Call options by funds: $30.7M | Put options by funds: $1.23M

28% more capital inflows, than outflows

Capital inflows: $191M | Capital outflows: $150M

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

0.07% more ownership

Funds ownership: 2.58% → 2.66% (+0.07%)

6% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 53

2% less funds holding

Funds holding: 313 → 307 (-6)

50% less repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 125

Holders
307
Holders Change
-6
Holders Change %
-1.92%
% of All Funds
4.46%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
50
Increased
63
Reduced
125
Closed
53
Calls
$30.7​M
Puts
$1.23​M
Net Calls
+$29.4​M
Net Calls Change
-⁠$10.6​M

TAK Hedge Fund Activity: Q4 2023 in Review

307 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q4 2023, worth a combined $1.19B — down 4.2% from $1.24B a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of TAK and 50 opened new positions — a net loss of 3 holders — while 125 trimmed existing stakes and 63 added.

The largest buyer was Mondrian Investment Partners, adding an estimated $58M. The largest seller was Bank of America, cutting an estimated $19.4M.

  • 307 institutional investors held Takeda Pharmaceutical (TAK) as of Q4 2023, down from 313 in Q3 2023.
  • Funds reported $1.19B of Takeda Pharmaceutical stock for Q4 2023, down 4.2% quarter-over-quarter.
  • 50 funds opened new Takeda Pharmaceutical positions in Q4 2023 and 53 closed out, a net change of -3 holders.
  • The largest Takeda Pharmaceutical buyer in Q4 2023 was Mondrian Investment Partners, an estimated $58M added.
  • The largest Takeda Pharmaceutical seller in Q4 2023 was Bank of America, an estimated $19.4M sold.

Based on aggregated 13F filings for Q4 2023.